**Timely Recognition, Management, and Referral of Axial Spondyloarthritis**

|  |  |
| --- | --- |
| Resource | Address |
| Raychaudhuri SP, Deodhar A. **The classification and diagnostic criteria of ankylosing spondylitis.***J Autoimmun*. 2014;48-49:128-133. | <https://pubmed.ncbi.nlm.nih.gov/24534717/> |
| Rudwaleit M, van der Heijde D, Landewé R, et al. **The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): Validation and final selection.** *Ann Rheum Dis*. 2009; 68:777-783. | <https://pubmed.ncbi.nlm.nih.gov/19297344/> |
| Garg N, van den Bosch F, Deodhar A. **The concept of spondyloarthritis: Where are we now?** *Best Pract Res Clin Rheumatol.* 2014;28:663-672. | <https://pubmed.ncbi.nlm.nih.gov/25488776/> |
| van den Berg R, de Hooge M, Rudwaleit M, et al. **ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: Results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort.** *Ann Rheum Dis*. 2013;72:1646–1653. | <https://pubmed.ncbi.nlm.nih.gov/23139266/> |
| Sieper J, Poddubnyy D. **Axial spondyloarthritis.** *Lancet*. 2017;390:73-84. | <https://pubmed.ncbi.nlm.nih.gov/28110981/> |
| Weber U, Lambert RG, Østergaard M, Hodler J, Pedersen SJ, Maksymowych WP. **The diagnostic utility of magnetic resonance imaging in spondylarthritis: An international multicenter evaluation of one hundred eighty-seven subjects.** *Arthritis Rheumatol.* 2010;62:3048-3058. | <https://pubmed.ncbi.nlm.nih.gov/20496416/> |
| Weisman MH, Witter JP, Reveille JD. **The prevalence of inflammatory back pain: Population-based estimates from the US National Health and Nutrition Examination Survey, 2009-10.** *Ann Rheum Dis*. 2013;72:369-373. | <https://pubmed.ncbi.nlm.nih.gov/22791746/> |
| Reveille JD, Hirsch R, Dillon CF, Carroll MD, Weisman MH. **The prevalence of HLA-B27 in the US: Data from the US National Health and Nutrition Examination Survey, 2009.** *Arthritis Rheum*. 2012;64(5):1407-1411. | <https://pubmed.ncbi.nlm.nih.gov/22139851/> |
| Sieper J, Rudwaleit M. **Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care.** *Ann Rheum Dis* 2005;64:659-663. | <https://pubmed.ncbi.nlm.nih.gov/15528281/> |
| Taurog JD, Chhabra A, Colbert RA. **Ankylosing Spondylitis and Axial Spondyloarthritis**. *N Engl J Med*. 2016;374:2563-2574. | <https://pubmed.ncbi.nlm.nih.gov/27355535/> |
| Cua DJ, Sherlock JP. **Autoimmunity's collateral damage: Gut microbiota strikes 'back'.** *Nat Med.* 2011;17:1055–1056. | <https://pubmed.ncbi.nlm.nih.gov/21900923/> |
| Gravallese EM, Schett G. **Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.** *Nat Rev Rheumatol*. 2018;14:631-640. | <https://pubmed.ncbi.nlm.nih.gov/30266977/> |
| Ward MM, Deodhar A, Gensler LS, et al. **2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.** *Arthritis Care Res (Hoboken)*. 2019;71:1285-1299. | <https://pubmed.ncbi.nlm.nih.gov/31436026/> |
| Dagfinrud H, Kvien TK, Hagen KB. **Physiotherapy interventions for ankylosing spondylitis.** *Cochrane Database Syst Rev.* 2008;23:CD002822. | <https://pubmed.ncbi.nlm.nih.gov/18254008/> |
| Zochling J, Bohl-Bühler MH, Baraliakos X, Feldtkeller E, Braun J. **Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis--A population-based survey.** *Clin Rheumatol*. 2006; 25:794-800. | <https://pubmed.ncbi.nlm.nih.gov/16528455/> |
| Davis JC Jr, Van Der Heijde D, Braun J, et al. **Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial.** *Arthritis Rheum*. 2003;48:3230-3236. | <https://pubmed.ncbi.nlm.nih.gov/14613288/> |
| Braun J, Deodhar A, Dijkmans B, et al. **Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.** *Arthritis Rheum.* 2008;59:1270-1278. | <https://pubmed.ncbi.nlm.nih.gov/18759257/> |
| van der Heijde D, Kivitz A, Schiff MH, et al. **Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial.** *Arthritis Rheum.* 2006;54:2136-2146. | <https://pubmed.ncbi.nlm.nih.gov/16802350/> |
| Inman RD, Davis JC Jr, Heijde Dv, et al. **Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial.** *Arthritis Rheum.* 2008;58:3402-3412. | <https://pubmed.ncbi.nlm.nih.gov/18975305/> |
| Deodhar A, Reveille JD, Harrison DD, et al. **Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: Results through week 28 of the GO-ALIVE study.** *J Rheumatol.* 2018;45:341-348. | <https://pubmed.ncbi.nlm.nih.gov/29247154/> |
| Landewe R, Braun J, Deodhar A, et al. **Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.***Ann Rheum Dis.* 2014;73:39-47. | <https://pubmed.ncbi.nlm.nih.gov/24013647/> |
| Deodhar A, Gensler LS, Kay J, et al. **A fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis**. *Arthritis Rheumatol.* 2019;71:1101-1111. | <https://pubmed.ncbi.nlm.nih.gov/30848558/> |
| Baeten D, Sieper J, Braun J, et al. **Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.** *N Engl J Med*. 2015;373:2534-2548. | <https://pubmed.ncbi.nlm.nih.gov/26699169/> |
| van der Heijde D, Cheng-Chung Wei J, Dougados M, et al. **Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.** *Lancet.* 2018;392:2441-2451. | <https://pubmed.ncbi.nlm.nih.gov/30360964/> |
| Deodhar A, Poddubnyy D, Pacheco-Tena C, et al. **Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: Sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors.** *Arthritis Rheumatol.* 2019;71:599-611. | <https://pubmed.ncbi.nlm.nih.gov/30343531/> |
| Deodhar A, Blanco R, Dokoupilová E, et al. **Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: Primary results of a randomized, placebo-controlled phase III study.** *Arthritis Rheumatol.* 2020;73:110-120. | <https://pubmed.ncbi.nlm.nih.gov/32770640/> |
| Deodhar A, van der Heijde D, Gensler LS, et al. **Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): A randomised, placebo-controlled trial.** *Lancet*. 2020;395:53-64. | <https://pubmed.ncbi.nlm.nih.gov/31813637/> |
| Maksymowych WP, Dougados M, van der Heijde D, et al. **Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.** *Ann Rheum Dis*. 2016;75:1328-1335. | <https://pubmed.ncbi.nlm.nih.gov/26269397/> |
| Landewé R, Sieper J, Mease P, et al. **Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): A multicentre, randomised, double-blind study.** *Lancet.* 2018;392:134-144. | <https://pubmed.ncbi.nlm.nih.gov/29961640/> |
| Landewé RB, van der Heijde D, Dougados M, et al. **Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.** *Ann Rheum Dis.* 2020;79:920-928. | <https://pubmed.ncbi.nlm.nih.gov/32381562/> |
| Haroon N. Inman RD, Learch TJ, et al. **The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.** *Arthritis Rheum*. 2013;65:2645-2654. | <https://pubmed.ncbi.nlm.nih.gov/23818109/> |
| van der Heijde D, Gensler LS, Deodhar A, et al. **Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.** *Ann Rheum Dis*. 2020;79:595-604. | <https://pubmed.ncbi.nlm.nih.gov/32253184/> |
| van der Heijde D, Song IH, Pangan AL, et al. **Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): A multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.** *Lancet*. 2020;394:2108. | <https://pubmed.ncbi.nlm.nih.gov/31732180/> |